News

LHV Group Announces Financial Calendar for 2025

LHV Group Announces Financial Calendar for 2025

LHV Group's Financial Calendar for 2025

LHV Group has officially set its financial calendar for the upcoming 2025 financial year, providing vital insights into its fiscal activities.

Key Dates in the Financial Calendar

Throughout 2025, LHV Group aims to keep its shareholders and clients informed with timely disclosures and events. Below is the chronological schedule of the major financial activities planned for the year:

January to April

The calendar kicks off with the presentation of the unaudited results for Q4 2024 on February 11, followed by the financial plan disclosure on February 13. The early months also include a review of January’s financial performance on February 18, and by March 4, the audited results for the full year of 2024 will be available.

Mid-Year Financial Updates

Continuing into April, LHV Group plans to provide February’s results on March 12 and conduct its Annual General Meeting (AGM) on March 26, ensuring active participation from stakeholders. April 8 will mark the ex-dividend date, informing shareholders of dividend eligibility, followed by a report on Q1 interim results slated for April 22.

Subsequent Announcements

As the year progresses, LHV Group will maintain transparency by announcing results for each month and quarterly interim results. April's results will be shared on May 13, while results for May will emerge on June 17, with Q2 interim reports on July 22. This consistent information flow will enhance understanding and investment planning for shareholders and clients alike.

Detailed Calendar Overview

Here's an overview of the significant dates in 2025:

  • February 11: Q4 2024 and unaudited full-year results
  • February 13: Disclosure of Financial Plan
  • February 18: January results
  • March 4: Audited results for 2024
  • March 12: February results
  • March 26: Annual General Meeting
  • April 8: Ex-dividend date
  • April 22: Q1 interim results
  • May 13: April results
  • June 17: May results
  • July 22: Q2 interim results
  • August 12: July results
  • September 16: August results
  • October 21: Q3 interim results
  • November 18: October results
  • December 16: November results

About LHV Group

LHV Group stands as Estonia's foremost financial group and capital provider, with a robust framework to support a wide array of financial services. Its key subsidiaries include LHV Pank, LHV Varahaldus, LHV Kindlustus, and LHV Bank Limited. The group is proud to employ over 1,100 professionals dedicated to providing excellent service to its clientele.

As of late August, LHV Group’s banking services reach 441,000 individuals, while its pension funds manage investments for 118,000 active clients. Additionally, LHV Kindlustus ensures protection for 168,000 clients, highlighting the group's extensive community engagement.

Notably, LHV Bank Limited operates under a banking license from the United Kingdom, catering to international financial technology firms and extending lending services to small and medium-sized enterprises (SMEs).

Contact Information

For further inquiries, please reach out to:

Priit Rum
Communication Manager
Phone: +372 502 0786
Email: priit.rum@lhv.ee

Frequently Asked Questions

What is the significance of LHV Group's financial calendar?

The financial calendar is crucial as it outlines essential dates for financial disclosures, helping investors and stakeholders stay informed about the company's performance and strategic direction.

How often does LHV Group disclose financial results?

LHV Group discloses its financial results monthly and quarterly, ensuring transparency and regular updates for its clients and shareholders.

What subsidiaries operate under LHV Group?

LHV Group includes several subsidiaries, primarily LHV Pank, LHV Varahaldus, LHV Kindlustus, and LHV Bank Limited, each specializing in different financial services.

Who can attend the Annual General Meeting?

Any shareholder of LHV Group is encouraged to attend the Annual General Meeting, providing an opportunity to engage with the company's leadership and to vote on key matters.

How does LHV Group support small and medium enterprises?

LHV Bank Limited provides lending services tailored for small and medium-sized enterprises, facilitating their growth and financial health.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

BioVid Debuts AI to Mimic Physician Decision-Making

Updated Category News Views 47

Revolutionizing Understanding: BioVid Mimetics™ Now here's something that's shaking the research tree: BioVid's launching Mimetics™, and it's a big deal. They've come up with AI that can mirror how physicians think and decide. This ain't your run-of-the-mill tech stuff—it's groundbreaking in understanding physician decision-making. The Core: How Do Doctors Really...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 111

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
AZ Health Workers Step Up for Community Wellness

Updated Category News Views 4

Health Screenings: A Step Before the Hospital Sometimes it's the basics, like a plain old health screening, that can shift the tides from crisis to care. That's exactly where AZ Blue Health Choice and Zeihan ProHealth come into the picture, aiming to pin those health concerns before they spiral out of control. For your average Arizonan who finds healthcare as elusive as a...

Continue Reading
Enigmata Innovates AI Security with Finovifi Tie-Up

Updated Category News Views 94

Emerging AI Risks and Protective Measures AI in financial spaces is like walking a tightrope, there's potential but caution is crucial. Enter Enigmata, diving headfirst into this arena by shaking hands with the Finovifi Marketplace. Their aim? To bolster AI's promise without letting sensitive data slip through the cracks. Sentinel: A New Guard for Sensitive Data Let's not...

Continue Reading
Podcast Giants Converge in Tennessee for POD U Summit

Updated Category News Views 57

Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...

Continue Reading
Home Insurance Gaps: Risky Assumptions Uncovered

Updated Category News Views 53

Unseen Threats to Homeownership Safety Liability gaps in insurance are like those stubborn stains on the carpet you keep missing—nearly invisible until you're flat on your face. In Alpharetta and Fulton County, homes aren't as secure from financial pitfalls as their charming façades suggest. So, what's the danger that folks are glossing over here? Hidden Dangers of...

Continue Reading
Americas Cardroom Smashes Prize Pools; Bahamas Up Next

Updated Category News Views 49

Ah, poker. Where dreams are won with a flick of the wrist and a well-placed bluff. This week, it was all eyes on Americas Cardroom’s Dual Venom PKOs, and let me tell you, they didn't just meet expectations—they chewed them up and spat them out like yesterday's jam. Two Titans Crowned in Poker Showdown The action wrapped up with a jaw-dropping $6,862,500 prize pool....

Continue Reading
Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 37

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading
Savvy Moves: Avoiding Pitfalls When Buying Used Vans

Updated Category News Views 14

When you're eyeing a used work van, don't just kick the tires and jot down the mileage—there's a whole backyard BBQ checklist you need to chew through. Tony Collichio, the work van guru from Spencerport, lays it down for us, highlighting key questions to ask before pulling out the checkbook. And let me tell you, these aren’t your everyday 'how does it drive?' queries....

Continue Reading
Abbott's Oncodetect Test: Game-Changer for Cancer Recurrence

Updated Category News Views 4

Pioneering Progress in Colorectal Cancer Detection There's a new player in the world of cancer diagnostics, and it's setting a fresh standard. Abbott's Oncodetect test, featured at the ESMO Congress, has shown a profound leap in sensitivity—30 percent over the older whole-exome sequencing approach. For those doing the math on the stock charts, Abbott (NYSE: ABT) is...

Continue Reading

Top 5 Most Recently Viewed Articles

Clare Locke Advocates for Megan Thee Stallion in Defamation Case

Updated Category News Views 111

Clare Locke LLP Champions Megan Thee Stallion's Defamation Case Clare Locke LLP, a respected name in defamation law, has taken a bold step to support Megan Thee Stallion's pursuit of justice against Milagro Cooper. The firm has filed a motion for leave to present an amicus brief that specifically endorses Megan's effort to have a jury's defamation ruling reinstated. This...

Continue Reading
Bankers Signal Looming Economic Challenges Amid Uncertainty

Updated Category News Views 167

Bankers Signal Looming Economic Challenges Amid Uncertainty Interest rate fluctuations, credit quality, and tariffs are significant concerns for financial institutions. A recent survey highlights the anxiety among bankers regarding the economic climate and impending recession. Survey Highlights Economic Fears According to a survey from fintech IntraFi, which gathered...

Continue Reading
Dave Portnoy Questions Elon Musk Amid Tesla's Plummeting Stock

Updated Category News Views 162

Tesla's Stock Dilemma: Portnoy's Concerns Tesla’s stock, designated as TSLA, has recently experienced a significant decline, stirring up discussions among investors and enthusiasts alike. Dave Portnoy, the founder of Barstool Sports, has voiced his frustration regarding this situation, bringing forth some pointed questions about Elon Musk’s priorities. In a recent...

Continue Reading
Akropolis Group's Credit Rating Affirmed Amid Strategic Changes

Updated Category News Views 88

Akropolis Group’s Robust Credit Rating Amid Strategic Reassessments Renowned international credit rating agency S&P Global Ratings recently evaluated the financial outlook for Akropolis Group, a prominent player in the real estate development and management sector. This assessment took into account significant structural governance changes within the Vilniaus Prekyba...

Continue Reading
Arcutis Takes a Significant Step with ZORYVE Cream for Kids

Updated Category News Views 156

Arcutis Advances ZORYVE® Cream for Pediatric Use Arcutis Biotherapeutics, Inc. is making headlines with its recent submission of a supplemental New Drug Application (sNDA) aimed at expanding the use of ZORYVE (roflumilast) cream 0.3% to treat plaque psoriasis in children as young as 2 years old. If approved, ZORYVE would be the first topical PDE4 inhibitor specifically...

Continue Reading